Reported Reactions

Adverse event reports that FDA received

  • Search
  • Watch list

Injection site urticaria adverse event reports that record this term

Kind of term
MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on . The data have the reports that FDA received through .

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on .

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 23,912 adverse event reports that record the MedDRA preferred term Injection site urticaria. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 2,075 reports in the 12 months to June 2026 and 1,855 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 127 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Drugs that the reports with the term Injection site urticaria name as a suspect product, in order of name
DrugClassReports with this term
ActemraInterleukin-6 receptor antagonist58
ActharAdrenocorticotropic hormone15
AdalimumabTumor necrosis factor blocker13
AdbryInterleukin-13 antagonist28
Aimovig189
Ajovy173
Alirocumab Prefilled Pen18
AmpyraPotassium channel blocker38
AplisolSkin test antigen11
Arcalyst18
AvonexInterferon beta106
BenadrylHistamine-1 receptor antagonist31
BenlystaB lymphocyte stimulator-specific inhibitor45
Betaseron98
Bimekizumab18
Bimzelx38
BotoxAcetylcholine release inhibitor50
BOTOX CosmeticAcetylcholine release inhibitor132
Bydureon138
Bydureon Bcise94
ByettaGLP-1 receptor agonist469
Certolizumab pegolTumor necrosis factor blocker100
Cetrotide10
CimziaTumor necrosis factor blocker189
Copaxone699
Corticotropin81
CosentyxInterleukin-17A antagonist124
Crysvita47
Daxibotulinumtoxin A-Lanm14
Device18
DupilumabInterleukin-4 receptor alpha antagonist133
DupixentInterleukin-4 receptor alpha antagonist3,677
DysportAcetylcholine release inhibitor14
EbglyssInterleukin-13 antagonist12
Egrifta Sv13
Emgality505
EnbrelTumor necrosis factor blocker5,185
EntyvioIntegrin receptor antagonist27
Evenity70
Extavia14
FasenraInterleukin-5 receptor alpha-directed cytolytic antibody16
FirazyrBradykinin B2 receptor antagonist24
ForteoParathyroid hormone analog270
Fuzeon12
Ganirelix acetateGonadotropin releasing hormone receptor antagonist14
Genotropin11
Glatiramer17
Glatiramer 40mg Pfs Inj24
Glatiramer acetate51
Glatiramer acetate injection75
Glatopa306
GoldStandardized chemical allergen20
HizentraHuman immunoglobulin G84
HumalogInsulin analog55
Human immunoglobulin gHuman immunoglobulin G15
Humatrope11
Humira3,424
Humira 40 Mg/0 8 Ml Pen201
Humira 40 Mg/0 8 Ml Pre-Filled Syringe30
Humulin NInsulin22
HydroxychloroquineAntimalarial21
Hydroxychloroquine sulfateAntimalarial16
IcatibantBradykinin B2 receptor antagonist10
ImitrexSerotonin-1b and Serotonin-1d receptor agonist17
Increlex18
Insulin glargineInsulin analog41
KesimptaCD20-directed cytolytic antibody32
KevzaraInterleukin-6 receptor antagonist133
KineretInterleukin-1 receptor antagonist326
Lanadelumab18
LantusInsulin analog20
Lantus SolostarInsulin analog22
LeflunomideAntirheumatic agent17
LevemirInsulin analog80
Makena235
MethotrexateFolate analog metabolic inhibitor116
Methotrexate sodiumFolate analog metabolic inhibitor30
MounjaroGLP-1 receptor agonist682
NovologInsulin analog11
NucalaInterleukin-5 antagonist55
OmalizumabAnti-IgE32
OmnitropeRecombinant human growth hormone13
OndansetronSerotonin-3 receptor antagonist16
OrenciaSelective T cell costimulation modulator51
OzempicGLP-1 receptor agonist34
Palynziq94
PegasysInterferon alpha13
PlaquenilAntimalarial15
PlegridyInterferon beta75
PraluentPCSK9 inhibitor94
PrednisoneCorticosteroid31
ProliaRANK ligand inhibitor29
Qwo11
RebifInterferon beta117
RemicadeTumor necrosis factor blocker24
RepathaPCSK9 inhibitor509
RibavirinNucleoside analog antiviral10
SaxendaGLP-1 receptor agonist68
SkyriziInterleukin-23 antagonist116
StelaraInterleukin-12 antagonist13
Strensiq140
SulfasalazineAminosalicylate24
Sumavel Dosepro78
Symlin11
TakhzyroPlasma kallikrein inhibitor12
TaltzInterleukin-17A antagonist661
Tanzeum32
TeduglutideGLP-2 analog13
Tezspire23
TirzepatideGLP-1 receptor agonist14
ToujeoInsulin analog11
TremfyaInterleukin-23 antagonist31
TresibaInsulin analog19
TrulicityGLP-1 receptor agonist464
Tryngolza13
Tymlos149
VedolizumabIntegrin receptor antagonist23
VelcadeProteasome inhibitor23
VictozaGLP-1 receptor agonist167
Victoza Solution for Injection 6mg/Ml24
Vivitrol43
Voxzogo27
WegovyGLP-1 receptor agonist21
XeominAcetylcholine release inhibitor33
XolairAnti-IgE138
ZepboundGLP-1 receptor agonist473
Zepbound KwikpenGLP-1 receptor agonist14

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 49 pharmacologic classes with 10 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Pharmacologic classes of the drugs that the reports with the term Injection site urticaria name, in order of name
ClassReports with this term
Acetylcholine release inhibitor236
Adrenocorticotropic hormone23
Aminosalicylate27
Anti-IgE175
Antimalarial52
Antirheumatic agent19
B lymphocyte stimulator-specific inhibitor48
Bradykinin B2 receptor antagonist34
CD20-directed cytolytic antibody36
Corticosteroid39
Folate analog metabolic inhibitor146
GLP-1 receptor agonist2,412
GLP-2 analog18
Gonadotropin releasing hormone receptor antagonist14
Histamine-1 receptor antagonist35
HMG-CoA reductase inhibitor12
Human immunoglobulin G114
Insulin42
Insulin analog287
Integrin receptor antagonist54
Interferon alpha13
Interferon beta298
Interleukin-1 receptor antagonist326
Interleukin-12 antagonist16
Interleukin-13 antagonist40
Interleukin-17A antagonist787
Interleukin-23 antagonist151
Interleukin-4 receptor alpha antagonist3,810
Interleukin-5 antagonist57
Interleukin-5 receptor alpha-directed cytolytic antibody18
Interleukin-6 receptor antagonist202
Nonsteroidal anti-inflammatory drug14
Nucleoside analog antiviral10
Opioid agonist22
Parathyroid hormone analog276
Partial opioid agonist14
PCSK9 inhibitor603
Plasma kallikrein inhibitor16
Potassium channel blocker38
Proteasome inhibitor23
RANK ligand inhibitor29
Recombinant human growth hormone18
Selective T cell costimulation modulator54
Serotonin-1b and Serotonin-1d receptor agonist21
Serotonin-3 receptor antagonist16
Skin test antigen20
Somatostatin analog12
Standardized chemical allergen20
Tumor necrosis factor blocker5,538

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Injection site urticaria, by month, five years to June 2026
025050020222023202420252026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Injection site urticaria
AgeReportsShareShare as a bar
Under 2290.1%
2 to 114601.9%
12 to 176612.8%
18 to 445,67123.7%
45 to 647,01729.3%
65 to 741,5746.6%
75 and over4271.8%
Age not given8,07333.8%
Sex of the patient in the reports that record Injection site urticaria
SexReportsShareShare as a bar
Female18,36776.8%
Male3,89516.3%
Unknown or not given1,6506.9%

Age and sex are as the report gives them. 95.3% of these reports give the United States as the country.

Terms near this one

Official pages

The site checked these addresses on . The links open in a new tab.

Cite this page

Reported Reactions. Injection site urticaria: adverse event reports that record this term. https://reportedreactions.com/reaction/injection-site-urticaria/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of . Reports received through .

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Injection site urticaria mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.

Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on .